[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Authorizes $4 Billion In Additional Share Repurchases",
    "summary": "By Roshan Fernandez Vertex Pharmaceuticals has authorized an additional share repurchase program of up to $4 billion. The program does not have an expiration date and can be discontinued at...",
    "url": "https://finnhub.io/api/news?id=58cffa6437c1f667f85e3b4447f6b82e926e614cda30db9f115e33b89b49798e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747674668,
      "headline": "Vertex Pharmaceuticals Authorizes $4 Billion In Additional Share Repurchases",
      "id": 134603209,
      "image": "",
      "related": "VRTX",
      "source": "Finnhub",
      "summary": "By Roshan Fernandez Vertex Pharmaceuticals has authorized an additional share repurchase program of up to $4 billion. The program does not have an expiration date and can be discontinued at...",
      "url": "https://finnhub.io/api/news?id=58cffa6437c1f667f85e3b4447f6b82e926e614cda30db9f115e33b89b49798e"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Inc - Authorizes $4 Billion Stock Repurchase Program - SEC Filing",
    "summary": "Vertex Pharmaceuticals Inc: * VERTEX PHARMACEUTICALS INC - AUTHORIZES $4 BILLION STOCKREPURCHASE PROGRAM - SEC FILINGSource text:Further company coverage: ...",
    "url": "https://finnhub.io/api/news?id=ee372dd64b907afca7486500f2f0803890d594c8de4f9b9c14b7de1200c96504",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747673350,
      "headline": "Vertex Pharmaceuticals Inc - Authorizes $4 Billion Stock Repurchase Program - SEC Filing",
      "id": 134603004,
      "image": "",
      "related": "VRTX",
      "source": "Finnhub",
      "summary": "Vertex Pharmaceuticals Inc: * VERTEX PHARMACEUTICALS INC - AUTHORIZES $4 BILLION STOCKREPURCHASE PROGRAM - SEC FILINGSource text:Further company coverage: ...",
      "url": "https://finnhub.io/api/news?id=ee372dd64b907afca7486500f2f0803890d594c8de4f9b9c14b7de1200c96504"
    }
  },
  {
    "ts": null,
    "headline": "VRTX Q1 Earnings Call: New Product Launches and Pipeline Progress Amid Revenue Miss",
    "summary": "Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 3% year on year to $2.77 billion. The company’s full-year revenue guidance of $11.88 billion at the midpoint came in 0.9% below analysts’ estimates. Its non-GAAP profit of $4.06 per share was 5.4% below analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=c37d3c965abc3b1dff53b50dfe2a58821374045c0ecf60d27efd2ddea2ff053e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747654586,
      "headline": "VRTX Q1 Earnings Call: New Product Launches and Pipeline Progress Amid Revenue Miss",
      "id": 134577390,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 3% year on year to $2.77 billion. The company’s full-year revenue guidance of $11.88 billion at the midpoint came in 0.9% below analysts’ estimates. Its non-GAAP profit of $4.06 per share was 5.4% below analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=c37d3c965abc3b1dff53b50dfe2a58821374045c0ecf60d27efd2ddea2ff053e"
    }
  },
  {
    "ts": null,
    "headline": "Janus Henderson Balanced Fund Q1 2025 Commentary",
    "summary": "The Fund returned -2.05% and the S&P 500Â®Index returned -4.27%. The Bloomberg U.S. Aggregate Bond Index returned 2.78%. The Balanced Index returned -1.45%.",
    "url": "https://finnhub.io/api/news?id=afd2de04e75f146aa407e807b818159d04600d690b1f9426f93ceada4148ab74",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747651560,
      "headline": "Janus Henderson Balanced Fund Q1 2025 Commentary",
      "id": 134580546,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2197655235/image_2197655235.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "The Fund returned -2.05% and the S&P 500Â®Index returned -4.27%. The Bloomberg U.S. Aggregate Bond Index returned 2.78%. The Balanced Index returned -1.45%.",
      "url": "https://finnhub.io/api/news?id=afd2de04e75f146aa407e807b818159d04600d690b1f9426f93ceada4148ab74"
    }
  },
  {
    "ts": null,
    "headline": "The Top Corporate Board Directors",
    "summary": "Who are the most influential directors at big publicly traded U.S. companies? The first annual Wall Street Journal ranking identifies 251 of them.",
    "url": "https://finnhub.io/api/news?id=066bfcda255c459bd0c85e53e67d6510547a1dc80926b2883fee079dac929bf7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747614660,
      "headline": "The Top Corporate Board Directors",
      "id": 134577269,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Who are the most influential directors at big publicly traded U.S. companies? The first annual Wall Street Journal ranking identifies 251 of them.",
      "url": "https://finnhub.io/api/news?id=066bfcda255c459bd0c85e53e67d6510547a1dc80926b2883fee079dac929bf7"
    }
  }
]